Mercer Global Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.75M | Buy |
13,961
+1,979
| +17% | +$249K | ﹤0.01% | 914 |
|
|
2025
Q1 | $1.33M | Sell |
11,982
-130
| -1% | -$14.4K | ﹤0.01% | 995 |
|
|
2024
Q4 | $1.65M | Buy |
12,112
+4,143
| +52% | +$566K | ﹤0.01% | 890 |
|
|
2024
Q3 | $911K | Sell |
7,969
-154
| -2% | -$17.6K | ﹤0.01% | 1052 |
|
|
2024
Q2 | $1.12M | Buy |
8,123
+430
| +6% | +$59.2K | ﹤0.01% | 925 |
|
|
2024
Q1 | $1.06M | Buy |
7,693
+2,401
| +45% | +$331K | ﹤0.01% | 937 |
|
|
2023
Q4 | $697K | Buy |
5,292
+1,219
| +30% | +$161K | ﹤0.01% | 1142 |
|
|
2023
Q3 | $458K | Buy |
4,073
+698
| +21% | +$78.5K | ﹤0.01% | 1294 |
|
|
2023
Q2 | $318K | Buy |
3,375
+121
| +4% | +$11.4K | ﹤0.01% | 1485 |
|
|
2023
Q1 | $329K | Buy |
3,254
+168
| +5% | +$17K | ﹤0.01% | 1453 |
|
|
2022
Q4 | $369K | Buy |
3,086
+259
| +9% | +$31K | ﹤0.01% | 1382 |
|
|
2022
Q3 | $300K | Sell |
2,827
-540
| -16% | -$57.3K | ﹤0.01% | 1409 |
|
|
2022
Q2 | $328K | Buy |
3,367
+430
| +15% | +$41.9K | ﹤0.01% | 1380 |
|
|
2022
Q1 | $275K | Buy |
+2,937
| New | +$275K | ﹤0.01% | 1555 |
|
|
2021
Q2 | – | Sell |
-2,960
| Closed | -$288K | – | 1712 |
|
|
2021
Q1 | $288K | Buy |
2,960
+568
| +24% | +$55.3K | ﹤0.01% | 1328 |
|
|
2020
Q4 | $229K | Buy |
+2,392
| New | +$229K | ﹤0.01% | 1175 |
|
|
2020
Q3 | – | Sell |
-1,842
| Closed | -$225K | – | 1270 |
|
|
2020
Q2 | $225K | Buy |
+1,842
| New | +$225K | ﹤0.01% | 957 |
|